INTS vs IPHA

Intensity Therapeutics, Inc. vs Innate Pharma S.A. — Valuation Comparison 2026

INTS

Biotechnology
Intensity Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$4.42
Last close
Models
7/13
Active
VS

IPHA

Biotechnology
Innate Pharma S.A.
Quality
4.8
out of 10
Value Trap
26
LOW
Price
$1.74
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType INTS Fair ValueINTS Upside IPHA Fair ValueIPHA Upside
Bayesian DCF Intrinsic $3.24 -26.8% $0.54 -68.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.26 -95.1%
Dynamic NAV Asset-Based $8.03 +81.7% $0.87 -49.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INTS vs IPHA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INTS vs IPHA — Which Stock Is More Undervalued?

IPHA scores higher with a 4.8/10 quality rating vs INTS's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intensity Therapeutics, Inc. (INTS) and Innate Pharma S.A. (IPHA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INTS currently trades at $4.42 with a QOC of 3.7/10, while IPHA trades at $1.74 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).